A recent survey reveals that U.S. adults prioritizing metabolic health are shifting their diets, focusing on healthier choices over aesthetics. With an emphasis on snacking smarter and the impact of GLP-1 medications, the dairy industry has a significant opportunity to meet evolving consumer needs.
Danish pharmaceutical manufacturer Novo Nordisk announced that the FDA approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and adverse cardiovascular events.
High protein isn’t enough anymore in the yogurt category. Other necessary claims include zero sugar or no added sugar, lactose free, contains probiotics, clean label, and even high fiber. High-protein yogurts make up about 67% of the yogurt market. But formulating high-protein yogurts can be a challenge, explains KJ Burrington.
Designed for individuals who are incorporating GLP-1 medications into their routines, the new menu is intended to empower guests with great tasting, nutritional choices that complement their unique needs.
Spreading the word about dairy’s contributions to a healthy weight, and expanding the supporting science is key as obesity continues to be a serious health concern in the United States. Through dairy checkoff-funded research, the dairy industry has made it a priority to address the obesity epidemic and provide scientific insights into dairy’s role in achieving and maintaining a healthy weight. In addition, dairy foods can improve weight loss quality in adults by preserving muscle and bone while losing fat.